Eblasakimab治疗中重度特应性皮炎1b期多剂量递增研究
该1b期随机双盲研究纳入52例中重度特应性皮炎成人患者,每周皮下注射eblasakimab 200、400或600 mg或安慰剂共8周。主要终点为治疗中出现的不良事件发生率,安慰剂组47%、eblasakimab组71%,多为轻中度且未导致停药。
要点
- Eblasakimab阻断IL-4和IL-13经2型受体信号传导。
- 治疗中出现的不良事件安慰剂组47%、eblasakimab组71%,多为轻中度。
核心结论
- 中重度特应性皮炎成人患者接受eblasakimab治疗耐受性良好,且较安慰剂有显著临床改善。
研究设计与样本
- 1b期随机双盲研究,52例中重度特应性皮炎成人患者每周皮下注射eblasakimab 200、400或600 mg或安慰剂共8周。
- 主要终点为治疗中出现的不良事件发生率。
主要发现
- 治疗中出现的不良事件安慰剂组47%、eblasakimab组71%,多为轻中度且未导致研究中止。
- 其他关键次要医生报告和患者报告终点均达到。
关键数值与推荐
- EASI较基线改善至少50%、75%或90%为次要终点。
- 峰值瘙痒数字评定量表评分较基线百分比变化为次要终点。
临床怎么用
- 原文未报告临床实践推荐。
局限性
- 需要更长期研究确认eblasakimab在特应性皮炎患者中的安全性和疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Eblasakimab, an interleukin (IL)-13 receptor α1 antagonist, blocks IL-4 and IL-13 signaling through the type 2 receptor. OBJECTIVE: The safety and efficacy of eblasakimab was evaluated in adults with moderate-to-severe atopic dermatitis (AD). METHODS: In this phase 1b randomized, double-blinded study, 52 patients with moderate-to-severe AD received weekly subcutaneous injections of eblasakimab 200, 400, or 600 mg, or placebo for 8 weeks. Primary outcome was the incidence of treatment-emergent adverse events. Secondary outcomes included percentage change in the Eczema Area and Severity Index from baseline; Eczema Area and Severity Index improvement of at least 50%, 75%, or 90% from baseline; and percentage change in the peak-pruritus numeric rating scale score from baseline. RESULTS: Treatment-emergent adverse events were reported in 47% placebo and 71% eblasakimab patients; most were considered mild or moderate and did not lead to study discontinuation. At week 8 eblasakimab 600 mg showed statistically significant improvement in mean percentage change in Eczema Area and Severity Index versus placebo (-65% vs -27%, P = .014). Other key secondary physician- and patient-reported end points were met. LIMITATIONS: Longer studies are required to confirm eblasakimab safety and efficacy in AD patients. CONCLUSIONS: Treatment of adults with moderate-to-severe AD with eblasakimab was well-tolerated and associated with significant clinical improvements versus placebo.
引用
- Veverka KA, Thng STG, Silverberg JI, et al. Safety and efficacy of eblasakimab, an interleukin 13 receptor α1 monoclonal antibody, in adults with moderate-to-severe atopic dermatitis: A phase 1b, multiple-ascending dose study. J Am Acad Dermatol. 2023. PMID: 37866456. doi:10.1016/j.jaad.2023.10.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。